ClinicalTrials.gg
RecruitingNCT06781229OROBESITEUpdated May 8, 2026

Periodontal Microbiota of Patients Candidates for Bariatric Surgery With Body Mass Index Greater Than 30

An observational study in Bariatric Surgery and Obesity, Morbid, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by University Hospital, Toulouse · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
170
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Obesity, Morbid with a site in France — 13 open to participants now, 15 under way, none of them phase 3. Obesity, Morbid · France.

Planned enrollment
12th of 23
170 · median 170
Started
2025
with 2 others
Observational
23 of 66
6 open now
Primary completion
2028-02
later than 12 of 14 live
Registered
65th of 66
by date

Among the 66 studies in Obesity, Morbid with a site in France, this one is the 12th largest by planned enrollment of the 23 observational ones that give a count, is one of 3 that started in 2025, is one of 23 observational ones, reaches primary completion later than 12 of the 14 other live ones, and was the 65th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

13 of the 66 studies in Obesity, Morbid with a site in France are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Obesity, Morbid with a site in France, or all of them as a file.
02

Study summary

The goal of this observational study is to compare the microbiological composition of the periodontal plaque of obese people undergoing bariatric surgery according to their Body Mass Index. The main question it aims to answer is:

Does obese patients have different microbiote according to their obesity?

Obesity being classified in two groups :

  • group "obesity" for a BMI between 30 and 35
  • versus "morbid obesity" group with a BMIabove 35.

Participants who are scheduled to undergo bariatric surgery as part of their regular medical care will answer questions about their quality of life, hygiene habits, and saliva and periodontal samples will be taken.

Read the detailed description

The study is a non-interventional, single-centre, cross-sectional, comparative study with prospective and consecutive recruitment of participants.

Participants who are scheduled to undergo bariatric surgery as part of their regular medical care will

  1. during the odontological visit of approximately one hour:

    • complete standard odontology medical questionnaire
    • complete the dietary hygiene questionnaire: "Etude Nationale Nutrition Santé" questionnaire
    • complete 2 quality of life questionnaires: EQ-5D-5L questionnaire and GOHAI self-questionnaire
    • undergo clinical examination (visual examination and partial periodontal probing),
    • Radiological check-up (panoramic X-ray) and biological check-up (salivary and periodontal samples (non-invasive).
  2. During bariatric surgery, surgical techniques create surgical waste. From this operative waste, fragments of visceral adipose tissue may be recovered and, if the surgery so requires, subcutaneous adipose tissue (quantity recovered: 5g of visceral adipose tissue and 5g of subcutaneous adipose tissue). The samples taken will be stored in a hospital tissue bank with a view to possible future re-use. Each patient will be informed of this during the inclusion visit.
03

Conditions studied

  • Bariatric Surgery
  • Obesity, Morbid

Keywords

  • microbiological composition
  • obese
  • bypass
  • Body mass index
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Obese patients scheduled to undergo bariatric surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • greater than or equal to 30
  • Be on the list of patients scheduled for bariatric surgery,
  • Be able to receive information about the study and understand the information form in order to take part in the study. This implies mastering the French language,

Exclusion criteria

Exclusion Criteria:

  • Alcohol consumption >30g/d (men) or 20g/d (women),
  • Having taken antibiotics, prebiotics or probiotics in the month prior to inclusion (this has an influence on the composition of the patient's microbiota),
  • During pregnancy or breastfeeding,
  • For whom oral surgery is planned (surgery for benign or malignant tumours of the maxillary and mandibular bone bases), or with a history of oral surgery in the month prior to inclusion,
  • At risk of infection (existence of one or more of the following known chronic infectious diseases: , , and mononucleosis) and/or chronic renal insufficiency ( \< 60ml/min),
  • Patients with a general pathology that contraindicates the performance of diagnostic procedures such as periodontal probing (patients at high risk of infective endocarditis according to the ANSM).
  • Totally edentulous patients
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
170 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1 : obesity : 30 ≤ BMI < 35

    Obese patients with 30 ≤ BMI \< 35

  • Group 2 : morbid obesity : 35 ≤ BMI

    Morbid obese patients with 35 ≤ BMI

06

What researchers measure

Primary outcomes

  1. Taxonomic analysis

    Taxonomic analysis of the microbiological composition of the periodontal plaque between group 1 (obesity) and 2 (morbid obesity) : relative quantities of periodontal bacteria between group 1 (obesity) and 2 (morbid obesity)

    Time frame: before bariatric surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 36 months is below that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Feb 3, 2025
Primary completionEst.
Feb 3, 2028
CompletionEst.
Feb 3, 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06781229
Responsible party
Sponsor
First posted
Jan 17, 2025
Start date
Feb 3, 2025
Primary completion
Feb 3, 2028 (estimated)
Completion
Feb 3, 2028 (estimated)
Last update
May 8, 2026

Study contacts

Stephanie BRAYER, Clinical Trial Assistant, master's degree
Contact
Brayer.Stephanie@iuct-oncopole.fr
0561322509

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion